Chelating Polymers for Hereditary Hemochromatosis Treatment.

  title={Chelating Polymers for Hereditary Hemochromatosis Treatment.},
  author={Ondřej Groborz and Lenka Poľakov{\'a} and Krist{\'y}na Kolouchov{\'a} and Pavel {\vS}vec and Lenka Loukotov{\'a} and Vijay Madhav Miriyala and Pavla Francov{\'a} and Jan Ku{\vc}ka and Jan Krijt and Petr P{\'a}ral and Martin B{\'a}je{\vc}n{\'y} and Tom{\'a}{\vs} Heizer and Radek Pohl and David Scott Dunlop and Jiř{\'i} Czernek and Luděk {\vS}efc and Jiř{\'i} Bene{\vs} and Petr {\vS}těp{\'a}nek and Pavel Hobza and Martin Hrub{\'y}},
  journal={Macromolecular bioscience},
Hemochromatosis (iron overload) encompasses a group of diseases that are characterized by a toxic hyperaccumulation of iron in parenchymal organs. Currently, only few treatments for this disease have been approved; however, all these treatments possess severe side effects. In this study, a paradigm for hemochromatosis maintenance/preventive therapy is investigated: polymers with negligible systemic biological availability form stable complexes with iron ions in the gastrointestinal tract, which… 

Chelators for Treatment of Iron and Copper Overload: Shift from Low-Molecular-Weight Compounds to Polymers

Critical evaluation of this new perspective polymer approach, which shows vivid potential to keep the therapeutic efficacy of low-molecular-weight agents, while avoiding their drawbacks, especially their side effects, is the purpose of this review article.



Iron binding dendrimers: a novel approach for the treatment of haemochromatosis.

A hydroxypyridinone-based dendrimer was demonstrated to be highly efficient at reducing the absorption of iron(III) in rat intestine and may find an application in the treatment of iron overload.

Nonabsorbable Iron Binding Polymers Prevent Dietary Iron Absorption for the Treatment of Iron Overload.

IBPs are a novel, nonabsorbable iron binding polymers that bind and sequester iron within the gastrointestinal (GI) tract that may ultimately prevent iron absorption as a safe alternative to iron chelation therapies for patients with hemochromatosis or other iron overload diseases.

Iron mobilization using chelation and phlebotomy.

Current approach to hemochromatosis.

Renal clearable nanochelators for iron overload therapy

This renal clearable nanochelator significantly reduces kidney damage caused by iron overload without demonstrating DFO’s own nephrotoxicity and provides enhanced efficacy and safety.

Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment.

The role of hepcidin in the pathogenesis of hemochromatosis reveals its similarities to endocrine diseases such as diabetes and indicates new approaches to diagnosis and management of this common disorder in iron metabolism.

Hydroxamic acid-containing hydrogels for nonabsorbed iron chelation therapy: synthesis, characterization, and biological evaluation.

Hydrogels containing pendant hydroxamic acid groups have been synthesized as potential nonabsorbed chelators for iron in the gastrointestinal tract and prevented an increase in serum hemoglobin and hematocrit levels in the animals, thus suggesting the prevention of systemic absorption of dietary iron from theintestinal tract.

HFE-associated hereditary hemochromatosis

In populations of northern European descent, the p.C282Y mutation in the HFE gene is highly prevalent, and HFE-associated hereditary hemochromatosis is the most common type of inherited iron overload disorder, postulated to be the mechanism for iron overload in this condition.

Iron metabolism in the erythrophagocytosing Kupffer cell

The inflammatory state, characterized by hypoferremia due to impaired processing or release of iron by the reticuloendothelial system, may be modeled in vitro when serum from rats bearing turpentine‐induced abscesses is included in the culture medium.

EASL clinical practice guidelines for HFE hemochromatosis.

  • Jia Ji-don
  • Medicine, Biology
    Journal of hepatology
  • 2010